Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Whether given every four or eight weeks, long-acting injections of cabotegravir and rilpivirine suppressed HIV equally well.
A majority of women interviewed in a small study expressed a preference for monthly injectable treatment over daily pills.
A rundown of POZ’s reporting on the 2020 Conference on Retroviruses and Opportunistic Infections
The Food and Drug Administration declined approval of ViiV Healthcare’s injectable HIV regimen Cabenuva.
The FDA recently held up the U.S. approval based on concerns over the monthly injectable regimen’s manufacturing.
Attendees will hear news about the second probable HIV cure, long-acting injectable meds and COVID-19.
The agency expressed concerns about the monthly injectable regimen’s chemistry and manufacturing controls.
A small study surveyed individuals about their preferences regarding long-acting injectable antiretroviral treatment.
Here are the HIV treatment news stories with the most views this year.
New forms of treatment and PrEP and, hopefully, an at least partially effective vaccine will be key to fighting the epidemic in the 2020s.
As long-acting injectables near approval, daily pill versions of the same drugs show long-term benefit.
Surveys reveal difficulties associated with daily pills and a desire for long-acting injectable therapy.
Recently, ViiV Healthcare applied for approval of the first long-acting injectable HIV regimen.
The experimental long-acting injectable regimen of cabotegravir and rilpivirine stands poised for approval.
Given every four weeks, the combo injection of cabotegravir and Edurant (rilpivirine) will likely face an FDA decision by early 2020.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.